Testing mitomycin before surgery for high-risk bladder cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether giving mitomycin directly into the bladder before surgery can help people with high-risk non-muscle-invasive bladder cancer. The goal is to see if this approach is safe and effective at preventing cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have high-risk non-muscle-invasive bladder cancer (as defined by your doctor).
- You must be in good enough health to walk around and take care of yourself (ECOG score 0 or 1).
- You must have had no other cancer in the last 5 years (except for certain low-risk cancers like some skin or prostate cancers).
- Your liver, kidney, and blood counts must be within a safe range before starting.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two medications—disitamab vedotin (a targeted therapy) and mitomycin C (a chemotherapy)—for people with early-stage bladder cancer that has a specific protein called HER2. The goal is to prevent cancer from coming back after surgery in people who cannot or will not receive BCG treatment.
This trial tests whether a chemotherapy drug placed directly into the bladder (chemoablation) works as well as surgery followed by chemotherapy for people whose low-grade bladder tumors have come back. It aims to find a less invasive option that still controls the cancer.
This study tests a combination of two chemotherapy drugs, mitomycin-C and gemcitabine, given directly into the bladder for people with high-risk bladder cancer that hasn't been controlled with BCG therapy. It's an option for those who can't or don't want to have their bladder removed.
This trial studies whether a medicine called mitomycin C given as a one-time bladder treatment right after ureteroscopy can reduce later recurrence (measured by urine test results and “IVR rate”). It may help people with non-spreading UTUC who are having endoscopic procedures and are planned for this standard add-on treatment.
This trial tests STM-416, given around the time you have surgery to remove recurring bladder tumors, to see if it can reduce the chance the cancer comes back. It is for people with high-risk early bladder cancer (non–muscle-invasive) who have already had standard treatment and now need another TURBT.
This trial tests a combination of chemotherapy and immunotherapy to treat large, non-invasive bladder cancer before and after surgery. It aims to avoid removing the bladder while still effectively treating the cancer.
Hear when a new Non-Muscle-Invasive Bladder Cancer (NMIBC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.